LTRN News & Events

Investor sentiment continues to hinge on developments out of the Middle East, and the market is still not buying the latest salvo from President Trump that U.S. negotiators are in "serious discussions" to end the war.  After opening broadly higher, indices ended the day mixed, with S&P 500's decline of 0.4% bringing the benchmark index within a percentage point of an official correction territory.  While the Vix retreated modestly, it remains above the 30 handle, and while Treasury yields saw a sharp reversal from the steel ascend since the start of the Iran campaign, the 10-year is still over 30bps higher as traders remains concerned by the inflationary slowdown as a result of rising energy prices.   Cyclical Industrials and Technology sectors were the worst performers, while defensively-oriented Staples and Utilities outperformed.  In the evening hours, futures are little changed, though commodities are showing continued strain, with WTI Crude Oil futures up for fourth straight session, topping $104 per barrel.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Spruce Powerup 6.0%Progress Softwareup 1.3%DOWN AFTER EARNINGS -Phreesiadown 22.0%CVD Equipmentdown 10.8%Lantern Pharmadown 6.9%ALSO LOWER -PepGendown 44.4% after Phase 2 Freedom trial data

"2025 was a defining year for Lantern Pharma as we achieved clinical validation across multiple programs while establishing the foundation for our next phase of growth," said Panna Sharma, CEO & President of Lantern Pharma. "The encouraging and developing LP-300 Phase 2 HARMONIC observations, combined with successful Phase 1a completion for LP-184 and FDA IND clearance for our pediatric CNS cancer program through Starlight Therapeutics, represent transformational milestones that validate and strengthen our AI-driven approach to precision oncology. Our full-year results reflect disciplined execution with a 19% reduction in total operating expenses year-over-year, even as we advanced multiple clinical programs through key inflection points and introduced a highly unique multi-agentic system aimed at conquering rare cancers. As we move into 2026, we are positioning to advance multiple high-value clinical programs, expand our RADR platform's commercial reach and revenue potential globally through our new AI Center of Excellence in India and strengthen our balance sheet."

Lantern Pharma and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared the Investigational New Drug, IND, application for STAR-001 in a planned Phase 1 pediatric clinical trial. STAR-001 is a precision oncology compound whose CNS and pediatric CNS indications were initially identified using Lantern's proprietary RADR AI platform. The planned trial will evaluate STAR-001 as a single agent and in combination with spironolactone in pediatric patients with relapsed or refractory central nervous system malignancies. The trial is planned to be conducted in collaboration with POETIC - the Pediatric Oncology Experimental Therapeutics Investigators' Consortium - a multicenter network of 14 leading academic children's cancer centers across the United States, Canada, and Israel.